VCYT logo

Veracyte (VCYT) News & Sentiment

Veracyte (VCYT) Surged on Reporting Strong Earnings
Veracyte (VCYT) Surged on Reporting Strong Earnings
Veracyte (VCYT) Surged on Reporting Strong Earnings
VCYT
Insider MonkeyMarch 10, 2025

Artisan Partners, an investment management firm, published its fourth quarter 2024 investor letter for the "Artisan Small Cap Fund." You can download the letter here. US stocks had a successful year, showing significant growth in Q4, although the portfolio's performance was stable and slightly lagged behind the Russell 2000® Growth Index.

Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
VCYT
ZacksFebruary 27, 2025

FMS, MASI, and VCYT from the Zacks Medical Instruments sector are good investment options due to their use of genAI, strategic growth, and solid financial health. However, challenges like geopolitical tensions and problems with wages and supplies could affect their future performance.

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
VCYT
zacks.comFebruary 25, 2025

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
VCYT
seekingalpha.comFebruary 24, 2025

Veracyte, Inc. (NASDAQ:VCYT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research, LLC Mason Carrico - Stephens Inc. Puneet Souda - Leerink Partners Maggie Boeye - William Blair & Company Lu Li - UBS Group AG Corey Rosenbaum - Scotiabank Subbu Nambi - Guggenheim Securities, LLC Yuko Oku - Morgan Stanley Joseph Conway - Needham & Company, LLC Prashant Kota - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Veracyte Fourth Quarter and Full Year 2024 Financial Results webcast.

Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates
Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates
Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates
VCYT
zacks.comFebruary 24, 2025

Veracyte (VCYT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to loss of $0.04 per share a year ago.

Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
VCYT
ZacksFebruary 21, 2025

VCYT remains a focus for investors because of the impressive results from the Afirma and Decipher brands.

Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
VCYT
zacks.comFebruary 21, 2025

VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises.

Veracyte to Participate in Upcoming Investor Conferences
Veracyte to Participate in Upcoming Investor Conferences
Veracyte to Participate in Upcoming Investor Conferences
VCYT
businesswire.comFebruary 19, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 46th Annual Institutional Investors Conference – Orlando, FL Presentation on March 5th at 9:50 a.m. Eastern Time Leerink Partners Global Healthcare Conference – Miami, FL Fireside Chat on March 11th at 8:40 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by.

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
VCYT
businesswire.comFebruary 14, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research.

Veracyte Gains 44% in a Year: What's Driving the Stock?
Veracyte Gains 44% in a Year: What's Driving the Stock?
Veracyte Gains 44% in a Year: What's Driving the Stock?
VCYT
zacks.comJanuary 6, 2025

VCYT is gaining shares due to the strength of its Afirma and Decipher tests.